Live feed
Filing
SCHEDULE 13D/A
SCHEDULE 13D/A0000950170-25-006448·Damora Therapeutics, Inc.
Schedule 13D ownership disclosure
GALECTO INC
Common Stock, par value $0.00001 per share · CUSIP: 36322Q107
Event date: 2024-08-29
- Filing-level shares
- 99,913
- Percent of class
- 7.6%
- Novo Holdings A/SReported CIK 0001388325
Shares: 99,913 · Class: 7.6%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000950170-25-006448
- Form type
- SCHEDULE 13D/A
- Filer
- Damora Therapeutics, Inc.
- CIK
- CIK 1800315
- Filed
- Jan 16, 2025
- Reporting period
- Aug 29, 2024
- Description
- Schedule 13D beneficial ownership